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Purpose: To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the 
treatment of macular edema secondary to branch retinal vein occlusion.
Methods: This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal 
bevacizumab (1.25 mg/0.05 mL, 22 eyes) or triamcinolone acetonide (4 mg/0.1 mL, 28 eyes) as the only treatment 
for macular edema secondary to branch retinal vein occlusion; all patients had a post-injection follow-up duration 
of >24 weeks. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) 
by optical coherence tomography were measured for up to 24 weeks after injection.
Results: BCVA was improved at 1, 4, 8,12 weeks post-injection in the bevacizumab group, and at 1, 4, 8 weeks 
post-injection in the triamcinolone group. No significant difference was found between the two groups except at 12 
weeks. CMT decreased significantly within each group, and no significant difference between groups was found. 
In the bevacizumab group, no elevated IOP was observed, whereas IOP was significantly increased at 4, 8, and 
12 weeks after triamcinolone injection; IOP was therefore significantly different between the two groups.
Conclusions: Intravitreal bevacizumab is a comparatively simple treatment method that can effectively improve 
BCVA and reduce CMT without ocular and systemic complications. Consequently, intravitreal bevacizumab injections 
may be useful as both an alternative and primary treatment for macular edema secondary to branch retinal vein 
occlusion.
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Branch retinal vein occlusion (BRVO) is a common 
disease in which the retinal vein is compressed and occluded 
due to thickening of the arterial wall, primarily where the 
artery and vein cross.
1 Retinal hemorrhage, vitreous hem- 
orrhage, tractional retinal detachment, and macular edema 
due to BRVO lead to decreased visual acuity. Of these, 
macular edema is the most common cause of decreased vis- 
ual acuity.
2 Macular edema, characterized by high capillary 
pressure and abnormalities of the self-regulatory mecha- 
nism of the retinal bloodstream, is thought to occur due to 
leakage of body fluids and blood plasma components due to 
microaneurysms or damaged capillary endothelium because 
of the destruction of the normal blood and blood retinal 
barrier and pooling of these components at the outer plex- 
iform, molecular layer, or inner nuclear layer.
3,4
Several treatments to improve visual acuity and facilitate 
anatomic recovery from macular edema due to retinal vein 
occlusion have been developed. These include grid pattern 
laser photocoagulation, vitrectomy, and intravitreal triamci-
nolone acetonide injection. The Branch Vein Occlusion Study 
(BVOS) reported that grid pattern laser photocoagulation im-
proved visual acuity by up to 60%,
2 and many reports
 have 
shown that intravitreal triamcinolone acetonide injections 
are effective at improving visual acuity.
5,6 
However, intravitreal triamcinolone acetonide injections 
are also associated with complications such as the formation 
of cataracts and an increase in intraocular pressure.
7,8 Fur-
thermore, laser treatment of cases with media opacity, such 
as retinal hemorrhage, are challenging, and laser treatment is 
only effective for non-ischemi-type macular edema.
9 
Recently, it was reported that intravitreal anti-vascular 
endothelial growth factor (VEGF) antibody injections used 
to treat colon cancer had positive results on macular 
edema,
10-12 and these injections have been used to treat 
various ocular diseases such as choroidal neovascularization. 
Rosenfeld et al.
12 reported an improvement in visual 
acuity and a decrease in macular edema after intravitreal 
bevacizumab injection in patients with central retinal vein 
occlusion (CRVO). Similarly, Itturalde et al.
11 reported an Korean J Ophthalmol Vol.23, No.4, 2009
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Table 1. Comparison of patient demographics and characteristics of intravitreal bevacizumab and triamcinolone 
acetonide injection group
Bevacizumab 
injection group
Triamcinolone acetonide 
injection group
p-value between 
injection groups
Age (mean±SD, range) 56.86±9.64 (37-73) 59.42±11.56 (33-78) 0.407
*
Sex (%)
   Male
   Female
  10 (45.5)
  12 (54.5)
11 (39.3)
17 (60.7)
0.621
†
Pre injection BCVA (logMAR, mean±SD) 0.60±0.41 0.67±0.28 0.160
*
Pre injection CMT (μm, mean±SD) 399.64±128.32 466.39±121.29 0.057
*
Pre injection IOP (mmHg, mean±SD) 13.09±2.07 13.36±2.57 0.694
*
Mean time between injection and 
diagnosis (wk, range) 13.6 (0-22) 14.4 (8-28)
Associated systemic disease (%)
   Hypertension
   Diabetes mellitus
   Hyperlipidemia
14 (63.6)
  5 (22.7)
 2 (9.0)
16 (57.1)
 7 (25.0)
 3 (10.7)
BCVA=best corrected visual acuity; logMAR=logarithm of the minimal angle of resolution; CMT=center macular thickness; IOP=intraocular 
pressure.
*Independent t-test; 
†Chi-square test.
anatomic decrease in macular edema and an improvement of 
visual acuity after injection of bevacizuamb in 16 eyes. Jaissle 
et al.
10 reported similar results in BRVO patients. However, 
no study has compared intravitreal triamcinolone acetonide 
injection with intravitreal bevacizumab injection for macular 
edema secondary to BRVO. Thus, in this study, we compared 
the effects of intravitreal triamcinolone acetonide and bev- 
acizumab injections to treat macular edema secondary to 
BRVO.
Materials and Methods
This retrospective study included 50 eyes of 50 patients 
who received a single injection of intravitreal bevacizumab 
(1.25 mg/0.05 mL, 22 eyes) or triamcinolone acetonide (4 
mg/0.1 mL, 28 eyes) as the only treatment for macular edema 
from BRVO between October 2006 and December 2007. All 
patients had a post-injection follow- up time of  >24 weeks.
Before treatment, best corrected visual acuity (BCVA), 
intraocular pressure (IOP), slit lamp examination, fundus 
examination, and central macular thickness (CMT) measure-
ments based on optical coherence tomography were measured 
at baseline and at 1, 4, 8, 12, and 24 weeks after injection. 
Fluorescein angiography was also performed at baseline. 
BCVA was evaluated using a Snellen eye chart and conv- 
erted into the visual acuity of log MAR (logarithm of the 
minimal angle of resolution) for statistical analyses. IOP was 
measured by Goldmann applanation tonometry and CMT 
was measured using a central macular thickness map (based 
on a center with a 0.5 mm radius) determined using optical 
coherence tomography (Stratus OCT
TM; Carl Zeiss Meditec 
Inc., Dublin, CA, USA). To determine underlying diseases, 
the medical history of all patients was taken, and blood 
pressure, blood coagulation, serum lipid levels, and blood 
sugar levels were evaluated. 
We included macular edema cases that did not show foveal 
ischemia or subretinal, retinal, or vitreous hemorrhage upon 
fluorescein angiography and fundus photography with a 
visual acuity of under 20/40. If other media opacities were 
present that could account for the decrease in visual acuity 
such as corneal opacity, cataract, and vitreous hemorrhage, 
or if ischemic changeswere seen on fluorescein angiogra- 
phy, or if it was not clear whether the patient had ischemic 
type or non-ischemic type macular edema due to a severe 
retinal hemorrhage, the patient was excluded from the study. 
Patients who had previous treatment for macular edema or 
who had received treatments for other conditions such as 
laser treatment, intravitreal injection within 24 weeks were 
also excluded. 
After instilling 0.5% proparacaine hydochloride topical 
eye drops 3 times every 5 minutes for topical anesthesia, the 
eye was irrigated with 5% povidone iodine, opened using a 
lid retractor, and then injected through the pars plana 3.0 mm 
posterior to the limbus in pseudophakic eyes and 3.5 mm 
posterior to the limbus in phakic eyes using a 30 gauge 
needle. To control intraocular pressure after the injection, 
anterior chamber paracentesis (0.1 mL) was performed. 
After the injection, an ophthalmic solution of the topical anti-
microbial drug levofloxacin was administered 4 times per 
day for a week. 
SPSS ver. 12.0.1 (SPSS Inc., Chicago, IL, USA) was used 
for statistical analyses and the chi-square test, paired t-test, 
Wilcoxon signed-rank test, and Mann-Whitney U test were 
used. Statistical significance was set at p<0.05. 
Results
Twenty-two of 50 patients (22 of 50 eyes) received be-JY Kim and SP Park. COMPARATIVE STUDY OF BEVACIZUMAB AND TRIAMCINOLONE
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Time (wk)
Baseline 1 wk 4 wk 24 wk 12 wk (
†) wk 8
Baseline 1 wk 4 wk 8 wk 12 wk 24 wk
BCVA Bevacizumab
Triamcinolone
0.6045±0.4135
0.6679±0.2842
0.3182±0.3304
0.4107±0.2948
0.2727±0.3369
0.3179±0.2995
0.2364±0.2717
0.3500±0.3109
0.2364±0.2592
0.5464±0.3249
0.4955±0.2903
0.6357±0.3118
BCVA=best corrected visual acuity; logMAR=logarithm of the minimal angle of resolution.
Fig. 1. Comparison of the clinical course of best corrected visual acuity between the bevacizumab-injected eyes and triamcinolone acetonide- 
injected eyes in patients with macular edema secondary to branch retinal vein occlusion. The asterisk (*) indicates a statistically significant changes
(p<0.05) from baseline within group, the dagger (†) means statistically significant difference (p<0.05) between the bevacizumab and tri-
amcinolone-injected eyes at each time point.
vacizumab injections. The male to female ratio in this patient 
group was 10 : 12, the mean age (±SD) was 56.86±9.64 
years, with a range of 37 to 73 years. The mean period from 
the development of symptoms to the injection was 13.6 
weeks (range, 0 to 22 weeks) (Table 1). 
Prior to the administration of the drugs, there were no 
significant differences in initial BCVA, CMT, or IOP (p- 
value=0.160, 0.057, 0.694, respectively) (Table 1). 
Bevacizumab-injected group
The mean BCVA (±SD) before intravitreal bevacizumab 
injection was logMAR +0.60±0.41 and after 1, 4, 8, 12, and 
24 weeks, it was logMAR +0.32±0.33, +0.27±0.34, +0.24± 
0.27, +0.24±0.26, and +0.50±0.29, respectively. At 1, 4, 8, 
and 12 weeks after the injections, there was a significant 
improvement from baseline within this group (p= 0.001 for 1, 
4, 8, and 12 weeks, respectively) (Fig. 1); however, no 
significant improvement was noted after 24 weeks (p=0.064 
at 24 weeks). The intraocular pressure (±SD) before the 
injection was 13.09±2.07 mmHg and at 1, 4, 8, 12, and 24 
weeks after the injection, the IOP in this group was 12.50 
±2.63, 12.23±2.72, 12.55±2.09, 12.0±2.78, and 12.32±2.92 
mmHg, respectively. Thus, during the follow-up period, 
there were no significant differences in IOP from baseline 
within the bevacizumab group (p=0.298, 0.67, 0.52, 0.52, 
0.162 at 1, 4, 8, 12, and 24 weeks) (Fig. 2). The thickness of 
macular edema based on the center macular thickness map 
generated by optical coherence tomography (±SD) was 
399.64±128.32 µm before the injection, and 322.32±112.45, 
281.59±94.46, 263.86±82.27, 271.18±81.51, and 297.32± 
86.56 µm at weeks 1, 4, 8, 12, and 24, respectively. This re- 
duction in macular thickness was significant for all follow-up 
periods when compared to baseline (p=0.001 for all post- 
injection periods vs. baseline) (Fig. 3). 
Triamcinolone-injected group
Intravitreal triamcinolone acetonide injections were used 
to treat 28 patients (28 eyes). The male:female ratio in this 
group was 11:17. The mean age (±SD) was 59.42±11.56 
years, with a range of 33 to 78 years, and the mean period 
from the development of symptoms to the injection was 14.4 
weeks (range, 8 to 28 weeks). BCVA (±SD) before the 
injection was log MAR +0.67±0.28, while the visual acuity 
after 1, 4, 8, 12, and 24 weeks was log MAR +0.41±0.29, 
+0.32± 0.30, +0.35±0.31, +0.55±0.32, and +0.64±0.31, 
respectively; the improvements after 1, 4, and 8 weeks were 
statistically significant (p=0.001 at 1, 4, and 8 weeks, p= 
0.070 at 12 weeks, p=0.539 at 24 weeks) (Fig. 1). In contrast 
to the bevacizumab group, however, IOP (±SD) was 
13.36±2.57 mmHg before the injection and increased to 
14.18±3.49, 15.39±5.33, 15.50±4.31, 14.54±3.07, and 13.50 
±3.09 mmHg after weeks 1, 4, 8, 12, and 24, respectively. 
The differences from baseline at 4 and 8 weeks were 
significant (p=0.550, 0.011, 0.016, 0.050, 0.554 for weeks 1, 
4, 8, 12, and 24, respectively) (Fig. 2). The increase in IOP 
during the follow-up periods exceeded 21 mmHg in 1 eye 
only, which indicates that although IOP increased 4 to 12 
weeks after the injection, it could be controlled by medication. 
CMT (±SD) was 466.39 ±121.29 µm before the injection but 
decreased to 359.18 ±113.70, 255.0±75.76, 263.10±105.0, 
298.07±108.94, and 356.68±106.06 µm 1, 4, 8, 12, and 24 
weeks after the injection, respectively; all these reduction in 
CMT in the triamcinolone group were significant (p=0.001 
for all follow-up periods) (Fig. 3).
Comparison of the Bevacizumab and Triamcinolone injection 
groups
BCVA did not show a significant difference between the Korean J Ophthalmol Vol.23, No.4, 2009
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Time (wk)
Baseline 1 wk 24 wk 8 wk (
†) 4 wk (
†) 12 wk (
†)
Baseline 1 wk 4 wk 8 wk 12 wk 24 wk
IOP Bevacizumab
Triamcinolone
13.0909±2.0681
13.3571±2.5706
12.5000±2.6322
14.1786±3.4859
12.2273±2.7243
15.3929±5.3287
12.5455±2.0949
15.5000±4.3076
12.000±2.7774
14.5357±3.0729
12.3182±2.9177
13.5000±3.0852
IOP=intraocular pressure, mmHg.
Fig. 2. Comparison of the clinical course of intraocular pressure between the bevacizumab-injected eyes and triamcinolone acetonide-injected 
eyes in patients with macular edema secondary to branch retinal vein occlusion. The asterisk (*) indicates a statistically significant changes (p 
<0.05) from baseline within group, the dagger (†) means statistically significant difference (p<0.05) between the bevacizumab and tri-
amcinolone-injected eyes at each time point.
Time (wk)
Baseline 1 wk 24 wk 8 wk 4 wk 12 wk
Baseline 1 wk 4 wk 8 wk 12 wk 24 wk
CMT Bevacizumab
Triamcinolone
399.6445±128.3204
466.3936±121.2869
322.3182±112.4503
359.1786±113.7049
281.5909±94.4591
255.0000±75.7554
263.8636±82.2720
263.1071±104.8971
271.1818±81.5058
298.0714±108.9386
297.3182±86.5565
356.6786±106.0569
CMT=Central macular thickness, μm.
Fig. 3. Comparison of the clinical course of central macular thickness between the bevacizumab-injected eyes and triamcinolone acetonide-injected
eyes in patients with macular edema secondary to branch retinal vein occlusion. The asterisk (*) indicates a statistically significant changes (p 
<0.05) from baseline within group.
two groups during the follow-up period except for 12 weeks 
after the injections (Mann-Whitney U test, p-value=0.132, 
0.317, 0.135, 0.000, 0.124 at 1, 4, 8, 12, and 24 weeks, 
respectively) (Fig. 1) and CMT was also not significantly 
different between the two groups throughout the follow-up 
period (Mann-Whitney U test, p-value=0.207, 0.309, 0.860, 
0.401, 0.062 at 1 ,4, 8, 12, and 24 weeks, respectively) (Fig. 
3). However, the IOP at 4, 8, and 12 weeks after the operation 
was statistically and significantly higher in the intravitreal 
triamcinolone acetonide-injected group than the intravitreal 
bevacizumab-injected group (Mann-Whitney U test, p- 
value=0.093, 0.006, 0.002, 0.001, 0.111 at 1, 4, 8, 12, and 24 
weeks, respectively) (Fig. 2). 
No cataracts occurred during the follow-up period as 
complications after the injection. Furthermore, no general 
complications or other ocular complications such as iris neo-
vascularization, neovascular glaucoma, retinal detachment, 
vitreal hemorrhage, or endophthalmitis were observed.
Case reports
Case 1. A 73-year-old female patient was referred to our 
hospital by the local clinic with a 2-week history of reduced 
visual acuity in the right eye. The medical history of the 
patient revealed that she had been diagnosed with 
hypertension 10 years previously and was currently been JY Kim and SP Park. COMPARATIVE STUDY OF BEVACIZUMAB AND TRIAMCINOLONE
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Fig. 4. Color fundus photograph, flourescein angiograph, optical coherence tomography at baseline, 4 wk, 12 wk (top row), 24 wk (bottom row) 
of case 1 after intravitreal injection of triamcinolone acetonide for macular edema in vein occlusion.
Fig. 5. Color fundus photograph, flourescein angiograph, optical coherence tomography at baseline, 4 wk, 12 wk (top row), 24 wk (bottom row) 
of case 2 after intravitreal injection of Bevacizumab for macular edema in vein occlusion.
treated for this. When she was referred to our hospital, her 
BCVA was 20/100. A flame-shaped retinal hemorrhage 
caused by branch retinal vein occlusion was seen upon 
fundus examination, and was accompanied by severe macular 
edema. No hyperfluorescence due to neovascularization 
or ischemic changes were observed upon fluorescein 
angiography. One week after intravitreal triamcinolone 
acetonide injection was performed, her visual acuity had 
improved and optical coherence tomography revealed a 
decrease in macular edema for up to 12 weeks, but macular 
edema recurred after 24 weeks, as did a decrease in the 
patient’s visual acuity (Fig. 4). 
Case 2. A 37-year-old female patient visited our hospital 
due to a dimming of vision in her left eye and a severe 
decrease in visual acuity 5 weeks prior. The patient had been 
diagnosed with hypertension 2 years previously and was 
currently taking oral medication for hypertension. The 
BCVA of the patient at the time of examination was 20/63. 
Fundus examination revealed a flame-shaped retinal 
hemorrhage and macular edema. Fluorescein angiography 
did not show hypofluorescence due to retinal hemorrhage. 
An intravitreal bevacizumab injection was administered, and 
the visual acuity of the patient improved from one week after 
the injection till 12 weeks; similarly, macular thickness 
decreased for up to 24 weeks (Fig. 5).
Discussion
Grid pattern laser photocoagulation and intravitreal tri-
amcinolone acetonide injections for BRVO improve visual 
acuity and decrease macular edema,
2,13 but these treatments 
have several limitations. Grid pattern laser photocoagulation 
is only effective for non-ischemic type BRVO and several 
treatment episodes are required.
14 Furthermore, if macular 
hemorrhage is present, it is difficult to treat immediately. If 
severe macular ischemia is present, treatment is ineffective.
15 
Intravitreal triamcinolone acetonide injections increase IOP, 
the formation of cataracts, and the occurrence of endoph-
thalmitis; furthermore, the long-term effectiveness of this 
treatment is also unclear.
8 
VEGF is a core mediator of intraocular neovascularization 
and macular edema, and animal experiments have shown that 
this molecule can promote ischemia caused by retinal vein 
occlusion. Furthermore, inhibition of VEGF is used to treat 
various conditions.
16-18 
In this study, we compared the effects of intravitreal tri-
amcinolone acetonide injections and bevacizumab injections. 
With regard to BCVA, although the bevacizumab group 
showed a significant improvement in visual acuity for up to 
12 weeks compared to baseline, while the triamcinolone 
group showed an improvement up to 8 weeks post-injection, 
the visual acuity after these time periods decreased in both 
groups and was not significantly different from the baseline 
values, consistent with existing studies. 
Rabena et al.
19 reported that macular edema accompanied 
by BRVO recurred after 2.1 months after intravitreal beva-
cizumab injection, while Wu et al.
20 and Badala
21 reported 
that the effects of intravitreal bevacizumab injection treatment 
for macular edema due to CRVO and BRVO disappeared 
after 6 weeks. Macular edema has also been reported to recur 
after intravitreal triamcinolone acetonide injection, although 
Krepler et al.
22 reported that improvements in macular edema Korean J Ophthalmol Vol.23, No.4, 2009
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and visual acuity in macular edema patients secondary to 
CRVO were observed for up to 3 months after intravitreal 
triamcinolone acetonide injection. 
We investigated improvements in visual acuity for a 
longer period than existing studies, and examined BRVO 
patients and patients without changes in ischemia and 
neovascularization, which may explain the differences 
between our findings and those reported in previous studies. 
Choi et al.
23 reported that patients with macular edema 
secondary to non-ischemic BRVO showed significant 
differences in macular edema thickness for up to 6 months 
after bevacizumab injection. Similarly, in our study, the 
thickness of macular edema after injection of either 
bevacizumab or triamcinolone acetonide decreased significantly 
throughout the follow-up period. However, although visual 
acuity improved significantly for up to 12 weeks and 8 weeks 
for bevacizumab or triamcinolone acetonide injections, 
respectively, after these time periods, it did not improve. 
These results indicate that injection of bevacizumab or 
triamcinolone acetonide decreases macular edema by 
reducing the thickness of macular edema, but several other 
factors also appeared to be involved in determining visual 
acuity. The visual acuity of BRVO patient is known to 
depend on how much blood circulation remains and the 
regeneration of blood circulation.
24,25 The foveal capillary 
plexus network contains the veins closest to the fovea; 
differences in the state of this capillary plexus network have 
been postulated to result in different visual outcomes in 
different cases. Clemett et al.
26 and Schilling and Jones
27 
reported that if the capillary plexus network is destroyed, 
visual outcomes are worse, while Kang et al.
28 reported the if 
the range of macular ischemia is small and the perifoveal 
capillary network is intact, the final visual acuity is better. 
The IOP after intravitreal triamcinolone acetonide 
injection increased significantly after 4, 8, and 12 weeks, but 
decreased to baseline after 24 weeks. The IOP exceeded 21 
mmHg in only one case, but was controlled by medication. In 
contrast, no increase in IOP was seen after bevacizumab 
injection and no systemic complications such as myocardial 
infarction and cerebral infarction were observed. 
Accordingly, intravitreal bevacizumab injections resulted 
in a temporary improvement in the visual acuity of macular 
edema patients secondary to BRVO and reduced macular 
thickness. Thus, intravitreal bevacizumab iassociated with 
fewer ocular complications than intravitreal triamcinolone 
acetonide injections, which is important when repeated 
injections are required. 
Thus, we conclude that intravitreal bevacizumab may be a 
better treatment option for macular edema secondary to 
BRVO than intravitreal triamcinolone acetonide injections. 
However, due to analysis of a limited number of patients, the 
absence of a control group, the limitations associated with a 
retrospective study, and the lack of inclusion of an ischemic 
BRVO group, more cases as well as control patients need to 
be evaluated to conclusively demonstrate the advantages of 
intravitreal bevacizumab injections versus intravitreal tri-
amcinolone acetonide injections for the treatment of macular 
edema secondary to BRVO.
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